Cilengitide targeting of α_vβ₃ integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenograftsBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer research (Baltimore). 2002, Vol 62, Num 15, pp 4263-4272, issn 0008-5472Article

Combined modality radioimmunotherapy: Promise and perilBURKE, Patricia A; DENARDO, Sally J; MIERS, Laird A et al.Cancer. 2002, Vol 94, Num 4, pp 1320-1331, issn 0008-543X, SUPConference Paper

Development of tumor targeting bioprobes (¹¹¹In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapyDENARDO, Sally J; DENARDO, Gerald L; MIERS, Laird A et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 7087s-7092s, issn 1078-0432, 2Conference Paper

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of ⁹⁰Y-DOTA-peptide-Lym-1 in lymphoma xenograftsTUSCANO, Joseph M; O'DONNELL, Robert T; MIERS, Laird A et al.Blood. 2003, Vol 101, Num 9, pp 3641-3647, issn 0006-4971, 7 p.Article